ECSP15013209A - Moléculas de enlace a il-18 - Google Patents

Moléculas de enlace a il-18

Info

Publication number
ECSP15013209A
ECSP15013209A ECIEPI201513209A ECPI201513209A ECSP15013209A EC SP15013209 A ECSP15013209 A EC SP15013209A EC IEPI201513209 A ECIEPI201513209 A EC IEPI201513209A EC PI201513209 A ECPI201513209 A EC PI201513209A EC SP15013209 A ECSP15013209 A EC SP15013209A
Authority
EC
Ecuador
Prior art keywords
epitope
linker molecule
amino acids
another embodiment
binds
Prior art date
Application number
ECIEPI201513209A
Other languages
English (en)
Inventor
Adina Eberth
Jean-Michel Rene Rondeau
Christian Carsten Silvester Kunz
Emma Michelle Campbell
Michael Otto Bardroff
Sylwia Marshall
Beate Diefenbachstreiber
Heeke Gino Anselmus Van
Barbara Brannetti
Jean-Marc Alfred Schlaeppi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP15013209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP15013209A publication Critical patent/ECSP15013209A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En un aspecto, la presente invención, por consiguiente, proporciona una molécula de enlace que se enlaza específicamente a IL-18, en donde la molécula de enlace no se enlaza al complejo de IL-18/proteína de enlace a IL-18 (IL-18BP), y en donde la molécula de enlace no es la IL-18BP. En una modalidad de este aspecto, la molécula de enlace se enlaza a un epítopo de IL-18 sobre IL-18, como se define con referencia a la SEQ ID NO: 1, en donde el epítopo comprende los aminoácidos Arg140 y Glu152. En otra modalidad de este aspecto, el epítopo puede comprender además cualquiera o más de los aminoácidos Gln92, Pro93, Gly95, Pro143, Glu157 o Glu177. En todavía otra modalidad de este aspecto, el epítopo puede comprender además cualquiera o más de los aminoácidos Lys89, 6 5 10 15 20 25 Arg94, Met96, Phe138, Ser141, Gly144, His145, Asp146, Gln150 o Leu180. En otra modalidad de este aspecto, la molécula de enlace no compite con IL-18BP por el enlace a IL-18 cuando la IL-18BP se enlaza a la IL-18.
ECIEPI201513209A 2012-09-07 2015-04-06 Moléculas de enlace a il-18 ECSP15013209A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261697981P 2012-09-07 2012-09-07

Publications (1)

Publication Number Publication Date
ECSP15013209A true ECSP15013209A (es) 2018-09-30

Family

ID=49596347

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201513209A ECSP15013209A (es) 2012-09-07 2015-04-06 Moléculas de enlace a il-18

Country Status (40)

Country Link
US (5) US9376489B2 (es)
EP (2) EP3725805A1 (es)
JP (3) JP6404817B2 (es)
KR (2) KR102330653B1 (es)
CN (2) CN109517065B (es)
AP (1) AP2015008266A0 (es)
AR (1) AR092465A1 (es)
AU (4) AU2013311234A1 (es)
BR (2) BR112015004783B1 (es)
CA (1) CA2883821C (es)
CL (1) CL2015000532A1 (es)
CO (1) CO7400884A2 (es)
CR (1) CR20150121A (es)
CU (1) CU24249B1 (es)
CY (1) CY1123071T1 (es)
DK (1) DK2892923T3 (es)
EA (2) EA034610B1 (es)
EC (1) ECSP15013209A (es)
ES (1) ES2804704T3 (es)
GT (1) GT201500054A (es)
HR (1) HRP20200906T1 (es)
HU (1) HUE050464T2 (es)
IL (2) IL237161B (es)
JO (2) JO3764B1 (es)
LT (1) LT2892923T (es)
MA (1) MA37892A1 (es)
MX (2) MX373426B (es)
MY (1) MY174691A (es)
PE (1) PE20150649A1 (es)
PH (1) PH12015500466B1 (es)
PL (1) PL2892923T3 (es)
PT (1) PT2892923T (es)
RS (1) RS60394B1 (es)
SG (2) SG11201501559VA (es)
SI (1) SI2892923T1 (es)
TN (1) TN2015000057A1 (es)
TW (2) TWI613217B (es)
UY (1) UY35016A (es)
WO (1) WO2014037899A2 (es)
ZA (1) ZA201500954B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376489B2 (en) * 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
ES2892923T3 (es) * 2013-09-05 2022-02-07 Ab2 Bio Sa Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias
WO2016020791A1 (en) * 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CA2972689A1 (en) 2015-03-05 2016-09-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
HUE057837T2 (hu) * 2015-11-03 2022-06-28 Janssen Biotech Inc PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
CN108218978B (zh) * 2016-12-13 2020-05-12 沈阳何氏眼产业集团有限公司 一种重组白细胞介素18及其制备方法与应用
US11352432B2 (en) 2017-03-09 2022-06-07 Mab Discovery Gmbh Antibodies specifically binding to human IL-1R7
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019213686A1 (en) * 2018-05-10 2019-11-14 The Council Of The Queensland Institute Of Medical Research Therapeutic compositions and uses therefor
EA202191122A1 (ru) * 2018-10-23 2021-07-19 Сколар Рок, Инк. СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ
US12269874B2 (en) 2018-12-03 2025-04-08 mAbProtein Co., Ltd. Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
CN109870570A (zh) * 2018-12-29 2019-06-11 广东云天抗体生物科技有限公司 一种检测猴il-18的酶联免疫试剂盒
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
EP4247847A1 (en) 2020-11-18 2023-09-27 Novartis AG Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
WO2022221264A1 (en) * 2021-04-12 2022-10-20 Ethos Biosciences, Inc. Methods and compositions for analysis of acute kidney injury
CA3219360A1 (en) 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
JPWO2023286694A1 (es) 2021-07-13 2023-01-19
WO2023134767A1 (zh) * 2022-01-14 2023-07-20 和径医药科技（上海）有限公司 一种靶向IL-18Rβ的抗体及其应用
US20250297018A1 (en) 2022-03-15 2025-09-25 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN120289645A (zh) * 2022-04-26 2025-07-11 诺华股份有限公司 靶向il-13和il-18的多特异性抗体
CN120858108A (zh) * 2023-01-06 2025-10-28 拉森医疗公司 抗il-18bp抗体
WO2024148243A1 (en) * 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025068957A1 (en) 2023-09-29 2025-04-03 Novartis Ag Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
CN120349413A (zh) * 2025-04-08 2025-07-22 生物岛实验室 Il-18纳米抗体、抗体对及其制备方法与应用
CN120349409B (zh) * 2025-04-08 2026-03-17 生物岛实验室 Il-18bp纳米抗体及其制备方法与应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
JPH03230220A (ja) 1990-02-05 1991-10-14 Seiko Epson Corp ソート処理方法
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
FI955798A7 (fi) 1993-06-03 1996-02-01 Therapeutic Antibodies Inc Terapeuttiset vasta-ainefrangmentit
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP2007121310A (ja) 1996-07-31 2007-05-17 Hayashibara Biochem Lab Inc 自己免疫疾患診断剤
JP2009047705A (ja) 1996-07-31 2009-03-05 Hayashibara Biochem Lab Inc 生物学的試料の検出方法
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DK1047781T3 (da) 1998-01-23 2004-12-06 Immunex Corp IL-18-receptorer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6432678B1 (en) 1999-06-21 2002-08-13 Smithkline Beecham Corporation Macaca cynomolgus IL 18
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
CA2381770C (en) 1999-08-24 2007-08-07 Medarex, Inc. Human ctla-4 antibodies and their uses
JP3230220B2 (ja) 1999-10-07 2001-11-19 独立行政法人 農業技術研究機構 ブタ由来インターロイキン−１８に対するモノクローナル抗体
CA2324168A1 (en) 1999-11-16 2001-05-16 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
KR100951067B1 (ko) 2000-02-10 2010-04-07 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고사용하는 방법
UA94022C2 (ru) * 2000-02-21 2011-04-11 Апплайд Резеч Системз Арс Холдинг Н.В. Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
EP1278540B1 (en) 2000-05-05 2008-05-14 Laboratoires Serono SA Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
PT1355668E (pt) 2001-01-29 2008-01-04 Serono Lab Utilização de inibidores da il-18 para o tratamento e/ou prevenção de doença cardíaca
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
AU2002365269A1 (en) 2001-10-26 2003-07-24 Centocor, Inc. Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
US9592267B2 (en) 2002-03-22 2017-03-14 Merck Serono Sa Use of IL-18BP for treatment of peripheral vascular diseases
FR2838444B1 (fr) 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
KR100988129B1 (ko) * 2003-04-30 2010-10-18 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
DK1622939T3 (da) 2003-05-13 2012-04-10 Merck Serono Sa Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
JP2005052021A (ja) 2003-08-07 2005-03-03 Yokohama City インターロイキン−１８変異体タンパク質
US20050075702A1 (en) 2003-10-01 2005-04-07 Medtronic, Inc. Device and method for inhibiting release of pro-inflammatory mediator
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005075648A1 (en) 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
WO2005079766A2 (en) 2004-02-20 2005-09-01 Novo Nordisk A/S Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
WO2005097998A2 (en) 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
CA2613204A1 (en) 2005-06-29 2007-01-11 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
TR201909609T4 (tr) 2005-08-23 2019-07-22 Univ Pennsylvania Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
JP4728785B2 (ja) 2005-11-30 2011-07-20 独立行政法人科学技術振興機構 Ｉｌ−１８の生物活性を有する新規ポリペプチドの生産方法、および当該ポリペプチドの産生を阻害する物質のスクリーニング方法
KR101416078B1 (ko) 2006-05-25 2014-07-07 글락소 그룹 리미티드 변형된 인간화 항­인터루킨­１８ 항체
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2009099545A1 (en) 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2326315A1 (en) 2008-08-18 2011-06-01 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
WO2010040736A2 (en) 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
KR20110071011A (ko) 2008-10-20 2011-06-27 아보트 러보러터리즈 Ｉｌ-18에 결합하는 항체 및 이의 정제 방법
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
KR20110105841A (ko) 2008-12-23 2011-09-27 엠티엔 모바일 머니 에스에이 (피티와이) 엘티디 거래를 안전하게 처리하기 위한 방법 및 시스템
US20110008766A1 (en) 2009-05-01 2011-01-13 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20120133382A (ko) 2010-02-09 2012-12-10 글락소 그룹 리미티드 대사 장애의 치료
US9255144B2 (en) * 2010-12-20 2016-02-09 Medimmune Limited Anti-IL-18 antibodies and their uses
US9376489B2 (en) * 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos

Also Published As

Publication number Publication date
EA201992614A3 (ru) 2020-05-31
AU2017272201A1 (en) 2018-01-04
CU24249B1 (es) 2017-02-02
IL268336A (en) 2019-09-26
AU2013311234A1 (en) 2015-03-05
KR102207672B1 (ko) 2021-01-26
HUE050464T2 (hu) 2020-12-28
US11111293B2 (en) 2021-09-07
GT201500054A (es) 2015-10-15
BR112015004783B1 (pt) 2023-01-31
BR122019028128B1 (pt) 2023-01-31
PH12015500466A1 (en) 2015-04-20
EA034610B1 (ru) 2020-02-27
SG11201501559VA (en) 2015-03-30
MX2015002986A (es) 2015-10-08
KR20210011504A (ko) 2021-02-01
US20220098296A1 (en) 2022-03-31
KR102330653B1 (ko) 2021-11-23
TWI655208B (zh) 2019-04-01
IL268336B (en) 2022-03-01
CN109517065A (zh) 2019-03-26
EP2892923A2 (en) 2015-07-15
JP6944509B2 (ja) 2021-10-06
US9376489B2 (en) 2016-06-28
IL237161B (en) 2019-08-29
KR20150047138A (ko) 2015-05-04
CU20150022A7 (es) 2015-08-27
RS60394B1 (sr) 2020-07-31
JOP20200308A1 (ar) 2020-11-29
ES2804704T3 (es) 2021-02-09
UY35016A (es) 2014-04-30
WO2014037899A2 (en) 2014-03-13
CO7400884A2 (es) 2015-09-30
IL237161A0 (en) 2015-04-30
AU2020201556A1 (en) 2020-03-19
JP2020072704A (ja) 2020-05-14
PH12015500466B1 (en) 2021-04-14
TW201827463A (zh) 2018-08-01
EA201992614A2 (ru) 2020-03-31
MY174691A (en) 2020-05-07
LT2892923T (lt) 2020-06-25
SI2892923T1 (sl) 2020-07-31
HRP20200906T1 (hr) 2020-09-04
JO3764B1 (ar) 2021-01-31
EP3725805A1 (en) 2020-10-21
JP2019037230A (ja) 2019-03-14
CN104640879B (zh) 2018-12-07
PT2892923T (pt) 2020-06-23
MX2020007022A (es) 2020-09-07
PL2892923T3 (pl) 2020-09-07
BR112015004783A2 (pt) 2017-11-21
US20190085068A1 (en) 2019-03-21
EA201590523A1 (ru) 2015-06-30
AU2016201741A1 (en) 2016-04-07
DK2892923T3 (da) 2020-06-29
US20250034240A1 (en) 2025-01-30
ZA201500954B (en) 2018-11-28
TW201414747A (zh) 2014-04-16
CR20150121A (es) 2015-05-04
HK1209136A1 (en) 2016-03-24
WO2014037899A3 (en) 2014-06-05
AR092465A1 (es) 2015-04-22
PE20150649A1 (es) 2015-05-14
EP2892923B1 (en) 2020-03-25
CN109517065B (zh) 2022-11-04
US20160376361A1 (en) 2016-12-29
US20140112915A1 (en) 2014-04-24
US10081677B2 (en) 2018-09-25
AU2017272201B2 (en) 2020-01-02
AU2020201556B2 (en) 2022-01-13
JP6404817B2 (ja) 2018-10-17
MA37892A1 (fr) 2016-06-30
MX373426B (es) 2020-06-25
CA2883821A1 (en) 2014-03-13
CA2883821C (en) 2023-03-07
CN104640879A (zh) 2015-05-20
TWI613217B (zh) 2018-02-01
CY1123071T1 (el) 2021-10-29
SG10201706623WA (en) 2017-09-28
AP2015008266A0 (en) 2015-02-28
TN2015000057A1 (en) 2016-06-29
CL2015000532A1 (es) 2015-06-05
AU2016201741B2 (en) 2017-09-07
JP2015534546A (ja) 2015-12-03

Similar Documents

Publication Publication Date Title
ECSP15013209A (es) Moléculas de enlace a il-18
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
MX360741B (es) Constructos de polipéptidos y sus usos.
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
EA201171325A1 (ru) Нуклеиновые кислоты, связывающиеся с гепсидином
AR085138A1 (es) VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
WO2014059442A8 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
CL2013003090A1 (es) Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso.
MX2014005728A (es) Anticuerpos especificos para antigeno de la superficie celular de trofoblasto-2 y sus usos.
EA201270174A1 (ru) Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
WO2013104804A3 (en) Dual antigen-induced bipartite functional complementation
CO6450689A2 (es) Variantes de unión a anti-albúmina de suero mejoradas
EA200970909A1 (ru) Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
CR20130128A (es) Nuevas proteínas de unión a antígenos
BR112013004341A2 (pt) composições pesticidas
CR20110559A (es) Anticuerpos específicos para cadherina-17
BR112014023415A2 (pt) moléculas que se ligam a ang2
JP2014518898A5 (es)
CR11059A (es) Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90
ECSP12011577A (es) Produccion recombinante de péptidos
EA201291065A1 (ru) Антитела против vla-4
UY32450A (es) Variantes de unión a anti-albúmina de suero mejoradas